CIK 0001826457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +5,407 | $13.41 | $73K | 66,019 |
| 2026-06-30 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −5,407 | $24.50 | $132K | 60,612 |
| 2026-06-30 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,407 | 81,093 | ||
| 2026-06-29 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +6,000 | $7.56 | $45K | 65,992 |
| 2026-06-29 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −6,000 | $22.95 | $138K | 59,992 |
| 2026-06-29 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 60,000 | ||
| 2026-06-24 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +30,000 | $7.56 | $227K | 89,992 |
| 2026-06-24 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −30,000 | $21.42 | $643K | 59,992 |
| 2026-06-24 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 66,000 | ||
| 2026-06-23 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +6,000 | $7.56 | $45K | 71,837 |
| 2026-06-23 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −11,845 | $20.22 | $240K | 59,992 |
| 2026-06-23 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 96,000 | ||
| 2026-02-23 | Janku Filip Chief Medical Officer | Sale | −9,189 | $19.50 | $179K | 65,837 |
| 2026-01-05 | Janku Filip Chief Medical Officer | Sale | −3,155 | $15.17 | $48K | 75,026 |
| 2026-01-02 | Janku Filip Chief Medical Officer | Grant or award | +31,000 | 78,181 | ||
| 2026-01-02 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +139,000 | 139,000 | ||
| 2025-01-02 | Janku Filip Chief Medical Officer | Grant or award | +36,000 | 45,189 | ||
| 2025-01-02 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +161,000 | 161,000 | ||
| 2024-09-13 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2024-01-02 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +121,000 | 121,000 |
Page 1 of 2 · 25 trades